EGFR Mutation Status and Subtypes Predicted by CT-Based 3D Radiomic Features in Lung Adenocarcinoma
Quan Chen,Yan Li,Qiguang Cheng,Juno Van Valkenburgh,Xiaotian Sun,Chuansheng Zheng,Ruiguang Zhang,Rong Yuan
DOI: https://doi.org/10.2147/ott.s352619
IF: 4
2022-06-02
OncoTargets and Therapy
Abstract:Quan Chen, 1, 2 Yan Li, 3 Qiguang Cheng, 1, 2 Juno Van Valkenburgh, 4 Xiaotian Sun, 1, 2 Chuansheng Zheng, 1, 2 Ruiguang Zhang, 5 Rong Yuan 6 1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; 2 Hubei Province Key Laboratory of Molecular Imaging, Wuhan, People's Republic of China; 3 Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; 4 Department of Radiology, Molecular Imaging Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; 5 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; 6 Department of Radiology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, People's Republic of China Correspondence: Ruiguang Zhang, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China, Email Rong Yuan, Department of Radiology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, People's Republic of China, Email Objective: In this study, we aim to establish a non-invasive tool to predict epidermal growth factor receptor (EGFR) mutation status and subtypes based on radiomic features of computed tomography (CT). Methods: A total of 233 lung adenocarcinoma patients were investigated and randomly divided into the training and test cohorts. In this study, 2300 radiomic features were extracted from original and filtered (Exponential, Laplacian of Gaussian, Logarithm, Gabor, Wavelet) CT images. The radiomic features were divided into four categories, including histogram, volumetric, morphologic, and texture features. An RF-BFE algorithm was developed to select the features for building the prediction models. Clinicopathological features (including age, gender, smoking status, TNM staging, maximum diameter, location, and growth pattern) were combined to establish an integrated model with radiomic features. ROC curve and AUC quantified the effectiveness of the predictor of EGFR mutation status and subtypes. Results: A set of 10 features were selected to predict EGFR mutation status between EGFR mutant and wild type, while 9 selected features were used to predict mutation subtypes between exon 19 deletion and exon 21 L858R mutation. To predict the EGFR mutation status, the AUC of the training cohort was 0.778 and the AUC of the test cohort was 0.765. To predict the EGFR mutation subtypes, the AUC of training cohort was 0.725 and the AUC of test cohort was 0.657. The integrated model showed the most optimal predictive performance with EGFR mutation status (AUC = 0.870 and 0.759) and subtypes (AUC = 0.797 and 0.554) in the training and test cohorts. Conclusion: CT-based radiomic features can extract information on tumor heterogeneity in lung adenocarcinoma. In addition, we have established a radiomic model and an integrated model to non-invasively predict the EGFR mutation status and subtypes of lung adenocarcinoma, which is conducive to saving clinical costs and guiding targeted therapy. Keywords: lung adenocarcinoma, epidermal growth factor receptor, gene mutation, radiomics, computed tomography Lung cancer is the leading cause of cancer-related deaths worldwide. 1 Lung adenocarcinoma is the most common type of non-small-cell lung cancers (NSCLC), which accounts for about 35–45% of lung malignant tumors. 2 Lung adenocarcinoma is composed of tumors with significant molecular heterogeneity, which is caused by different internal carcinogenic signal pathways and characterized by high rates of genetic mutation. 3 The epidermal growth factor receptor (EGFR) signaling pathway plays a vital role in a variety of lung cancers, especially lung adenocarcinoma. Multiple clinical trials have shown that first-line administration of EGFR-tyrosine kinase inhibitors (EGFR-TKI) can prolong progression-free survival (PFS) compared with chemotherapy for lung adenocarcinoma patients with EGFR mutations. 4–8 The most common mutations are exon 19 deletion (exon 19) and the exon 21 L858R mutation (exon 21). 9–11 It is worth mentioning that the exon 19 mutation has a better prognosis than the exon 21 mutation with EGFR-TKI. 12–14 Therefore, the detection of EGFR mutation status and subtypes is very important for guiding the targeted therapy of lung adenocarcinoma patients. Gene sequen -Abstract Truncated-
oncology,biotechnology & applied microbiology